The SCVC Blog

Cardiovascular care news and articles from our expert team

Protected: Mounjaro

Posted on Thursday December 12, 2024 in Medication

Cholesterol, LDL, and what we learnt from PCSK9 mutations in familial hypercholesterolaemia

PCSK9 binds to LDL receptors and directs them to be destroyed within the cell, rather than allowing them to recycle to the surface. When too much PCSK9 is present, fewer LDL receptors remain available to clear LDL from the blood. The result is simple: LDL levels rise. When that happens, the liver compensates by making even more cholesterol internally. This is why around 90% of the cholesterol in your blood is made by your liver, not absorbed from your diet.

UK Cholesterol, Apo B, LDL-C Targets

Small dense LDL (sdLDL) particles are the most atherogenic type of LDL. They are smaller and heavier, stay in the bloodstream longer and more likely to oxidise and enter artery walls. High sdLDL is typical of metabolic syndrome, diabetes, and high triglyceride states linked to visceral fat.Because sdLDL testing is specialised, the ApoB level and the LDL-C : ApoB ratio can be used to estimate particle size predominance:

Visceral Fat, Mitochondria, and the Energy Trap: Why We Store Fat Where We Shouldn’t

Visceral fat (VAT) is the dangerous, hidden fat stored around your organs that accumulates. when caloric intake exceeds energy demand, since glucose and fats that can’t be used gets stored as adipose tissue. This blog explains how ageing, muscle loss, glucose spikes and genetic factors all drive VAT accumulation — and how reversing the cycle requires restoring mitochondrial health, increasing muscle mass, and in many people, by reducing glycaemic overload.

Severe coronary disease diagnosed by CTCA

Written by Dr Edward Leatham, Consultant Cardiologist. Here we discuss non-invasive and invasive investigation techniques for investigation and diagnosis.